PharmaDrug Acquires 40% Stake in Canurta to Advance Botanical Therapeutics for ALS and Neurodegenerative Diseases
Key Insights
PharmaDrug Inc. (search) has executed a definitive agreement to acquire up to 40% equity interest in Canurta Inc. (search), a biotechnology company developing botanical therapeutics for inflammatory and neurodegenerative diseases (search).
The transaction will be completed in two tranches through the issuance of 83.6 million PharmaDrug shares, with the first closing scheduled for November 10, 2025, and the second by January 31, 2026.
Canurta's lead candidate CNR-401 is advancing toward Phase 2 clinical trials targeting Amyotrophic Lateral Sclerosis (search) (ALS (search)), utilizing the company's proprietary Polykye™ platform for multi-target botanical formulations.
PharmaDrug Inc. (search), a specialty pharmaceutical company focused on natural medicines research and development, has executed a definitive securities exchange agreement to acquire up to 40% equity interest in Canurta Inc. (search), a biotechnology company pioneering botanical therapeutics for inflammatory and neurodegenerative diseases (search). The strategic acquisition positions PharmaDrug to expand its biotechnology footprint while advancing Canurta's clinical pipeline, particularly its lead ALS (search) candidate CNR-401.
Transaction Structure and Timeline
The acquisition will be completed through two tranches involving the issuance of an aggregate 83,645,316 PharmaDrug common shares. At the first closing, scheduled for November 10, 2025, PharmaDrug will acquire 8,109,987 limited partner units representing 20% of outstanding units in exchange for 25,980,000 shares. The second tranche, requiring shareholder approval, will involve acquiring an additional 8,191,495 units for 57,665,316 shares by January 31, 2026.
PharmaDrug expects to hold a shareholder meeting in early January 2026 to approve the second tranche issuance. Upon completion of both tranches, Canurta will hold approximately 44% of PharmaDrug's issued and outstanding shares on a pro forma basis, while PharmaDrug will maintain its 40% interest in Canurta.
Canurta's Botanical Therapeutics Platform
Canurta Inc. (search) utilizes its proprietary Polykye™ platform to develop rare bioactive botanical ingredients and multi-target formulations designed to address complex disease mechanisms. The company's lead candidate, CNR-401, is advancing toward Phase 2 clinical trials targeting Amyotrophic Lateral Sclerosis (search) (ALS (search)), with a parallel strategy incorporating real-world evidence initiatives to accelerate global regulatory approval.
The biotechnology company has secured more than $13 million in combined equity, convertible debt, and non-dilutive funding while building a portfolio of over 20 global patents. Under the leadership of founder and CEO Akeem Gardner, Canurta focuses on addressing complex inflammatory and neurodegenerative diseases (search) through innovative botanical therapeutics.
Strategic Partnership Benefits
Dr. David Kideckel, Executive Chairman of PharmaDrug, emphasized the strategic importance of the partnership: "Executing the Definitive Agreement with Canurta represents a major milestone in our strategy to expand PharmaDrug's biotechnology footprint through innovative botanical drug development. This partnership enhances our clinical pipeline and supports our long-term growth objectives."
Akeem Gardner, Founder and CEO of Canurta, highlighted the collaboration's potential: "This agreement formalizes our collaboration with PharmaDrug to advance CNR-401 and other pipeline assets. We look forward to leveraging PharmaDrug's public market platform to scale Canurta's research and deliver value for patients and shareholders."
Transaction Terms and Protections
The definitive agreement includes customary representations and warranties, along with a recission right allowing Canurta's limited partners to require the return of transferred units if defined milestones are not met within agreed timelines. In such cases, corresponding PharmaDrug shares would be returned to treasury for cancellation, restoring the pre-closing ownership structure. The recission right expires no later than March 1, 2026.
As part of the transaction, Canurta will advance $85,000 to PharmaDrug at each closing through forgivable promissory notes bearing 12% annual interest to support working capital requirements. The transaction completion remains subject to customary closing conditions, including Canadian Securities Exchange approval and receipt of all required shareholder and regulatory approvals.